Compass Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Compass Therapeutics has a total shareholder equity of $146.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $155.6M and $9.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$146.23m |
| Equity | US$146.10m |
| Total liabilities | US$9.51m |
| Total assets | US$155.61m |
Recent financial health updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11Financial Position Analysis
Short Term Liabilities: CMPX's short term assets ($153.5M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: CMPX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CMPX is debt free.
Reducing Debt: CMPX has no debt compared to 5 years ago when its debt to equity ratio was 53.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMPX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CMPX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.8% each year